Patients with type 2 diabetes mellitus failing on oral agents and starting once daily insulin regimen; A small randomized study investigating effects of adding vildagliptin

BMC Research Notes

Volumn 7, Issue 1, 2014, Pages

  De Ranitz Greven, Wendela Lucia ^a   Beulens, Joline Wilhelma Johanna ^a   Hoeks, Lette Birgit Elisabeth Anne ^a   Belle Van Meerkerk, Gerdien ^a   Biesma, Douwe Hedde ^a   De Valk, Harold Wessel ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Clinical trial; DPP4 inhibitor; Insulin; Therapy vildagliptin

Indexed keywords

ADAMANTANE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE BLOOD LEVEL; INSULIN; NITRILE; PLACEBO; PYRROLIDINE DERIVATIVE; VILDAGLIPTIN;

ADULT; AGED; ANALOGS AND DERIVATIVES; ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

ADAMANTANE; ADMINISTRATION, ORAL; ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HUMANS; INSULIN; MALE; MIDDLE AGED; NITRILES; PLACEBOS; PYRROLIDINES;

EID: 84907989520     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-7-579     Document Type: Article

References (25)

1. U.K. Prospective Diabetes Study Group: U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995, 44:1249-1258.
2. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B: Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32:193-203.
3. Ahren B, Schweizer A, Dejager S, Dunning BE, Nilsson PM, Persson M, Foley JE: Vildagliptin enhances islet responsiveness to both hyper-and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab 2009, 94:1236-1243.
4. Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S: Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007, 50:1148-1155.
5. Arnolds S, Dellweg S, Clair J, Dain MP, Nauck MA, Rave K, Kapitza C: Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care 2010, 33:1509-1515.
6. Barnett AH, Charbonnel B, Donovan M, Fleming D, Chen R: Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Curr Med Res Opin 2012, 28:513-523.
7. Charbonnel B, Schweizer A, Dejager S: Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence? Hosp Pract (1995) 2013, 41:93-107.
8. Fonseca V, Baron M, Shao Q, Dejager S: Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus. Horm Metab Res 2008, 40:427-430.
9. Hong ES, Khang AR, Yoon JW, Kang SM, Choi SH, Park KS, Jang HC, Shin H, Walford GA, Lim S: Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study. Diabetes Obes Metab 2012, 14:795-802.
10. Kothny W, Foley J, Kozlovski P, Shao Q, Gallwitz B, Lukashevich V: Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2013, 15(3):252-257.
11. Lukashevich V, Schweizer A, Foley JE, Dickinson S, Groop PH, Kothny W: Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment. Vasc Health Risk Manag 2013, 9:21-28.
12. Rosenstock J, Rendell MS, Gross JL, Fleck PR, Wilson CA, Mekki Q: Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA (1C) without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab 2009, 11:1145-1152.
13. Schweizer A, Foley JE, Kothny W, Ahren B: Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin. Vasc Health Risk Manag 2013, 9:57-64.
14. Vilsboll T, Rosenstock J, Yki-Jarvinen H, Cefalu WT, Chen Y, Luo E, Musser B, Andryuk PJ, Ling Y, Kaufman KD, Amatruda JM, Engel SS, Katz L: Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2010, 12:167-177.
15. Currie CJ, Johnson JA: The safety profile of exogenous insulin in people with type 2 diabetes: justification for concern. Diabetes Obes Metab 2012, 14:1-4.
16. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR, American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD): Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012, 55:1577-1596.
17. Mori Y, Taniguchi Y, Miyazaki S, Yokoyama J, Utsunomiya K: Effects of add-on treatment with sitagliptin on narrowing the range of glucose fluctuations in Japanese type 2 diabetes patients receiving insulin therapy. Diabetes Technol Ther 2013, 15:237-240.
18. Shimoda S, Iwashita S, Ichimori S, Matsuo Y, Goto R, Maeda T, Matsuo T, Sekigami T, Kawashima J, Kondo T, Matsumura T, Motoshima H, Furukawa N, Nishida K, Araki E: Efficacy and safety of sitagliptin as add-on therapy on glycemic control and blood glucose fluctuation in Japanese type 2 diabetes subjects ongoing with multiple daily insulin injections therapy. Endocr J 2013, 60(10):1207-1214.
19. Van Genugten RE, Moller-Goede DL, Van Raalte DH, Diamant M: Extra-Pancreatic Effects of Incretin-Based Therapies: Potential Benefit for Cardiovascular Risk Management in Type 2 Diabetes. Diabetes Obes Metab 2013, 15(7):593-606.
20. Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R: Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 2005, 28:1282-1288.
21. Greven WL, Beulens JW, Biesma DH, Faiz S, De Valk HW: Glycemic variability in inadequately controlled type 1 diabetes and type 2 diabetes on intensive insulin therapy: a cross-sectional, observational study. Diabetes Technol Ther 2010, 12:695-699.
22. Meerwaldt R, Graaff R, Oomen PH, Links TP, Jager JJ, Alderson NL, Thorpe SR, Baynes JW, Gans RO, Smit AJ: Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 2004, 47:1324-1330.
23. Meerwaldt R, Links T, Graaff R, Thorpe SR, Baynes JW, Hartog J, Gans R, Smit A: Simple noninvasive measurement of skin autofluorescence. Ann N Y Acad Sci 2005, 1043:290-298.
24. Esposito K, Ciotola M, Maiorino MI, Gualdiero R, Schisano B, Ceriello A, Beneduce F, Feola G, Giugliano D: Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial. Ann Intern Med 2008, 149:531-539.
25. Kooy A, De JJ, Lehert P, Bets D, Wulffele MG, Donker AJ, Stehouwer CD: Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med 2009, 169:616-625.